Bristol Myers Squibb Invests $35 Million in Immatics
By Will Feuer
Bristol Myers Squibb has invested $35 million in clinical-stage biopharmaceutical company Immatics.
Bristol Myers bought about 2.42 million ordinary shares of Immatics in a private placement at a subscription price of $14.46 a share. Immatics shares rose 7.7% to $12.80 in premarket trading.
Immatics said Bristol Myers also has the right to appoint a member to the Immatics Scientific Advisory Board as part of the deal.
Immatics is focused on developing T cell receptors with the goal of enabling a robust and specific T cell response against targets for cancer immunotherapies.
"This investment is further testimony to the strength of the relationship and of our differentiated platform technologies that are the foundation of our TCR-based cell therapies and bispecifics," Immatics Chief Executive Harpreet Singh said.
Write to Will Feuer at Will.Feuer@wsj.com
(END) Dow Jones Newswires
July 24, 2023 07:41 ET (11:41 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
5 Things We Learned From the Q1 Earnings Season
-
After Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening In the Markets This Week
-
Can the Fed Declare Victory on Inflation?
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing
-
Going Into Earnings, Is Nvidia Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Arista Stock a Buy, a Sell, or Fairly Valued?
-
A Cheap Dividend Aristocrat to Buy Before It Bounces Back
-
Alibaba Earnings: More Positive Outlook Despite Mixed Results
-
After Earnings and a 56% Rally In 2024, Is Arm Stock a Buy, a Sell, or Fairly Valued?
-
How Morningstar Rates Stocks
-
After Earnings, Is Disney Stock a Buy, a Sell, or Fairly Valued?